AgomAb Therapeutics NV
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AGMB | AVBP | IMRX | ACRS | GPCR | CRVS | |
|---|---|---|---|---|---|---|
| Market cap | 447.66M | 811.61M | 249.73M | 529.92M | 1.71B | 845.42M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -4.4 | -4.2 | -3.1 | -4.6 | -11.3 | -9.4 |
| Price/book | 3.6 | 2.2 | 1.3 | 4.0 | 1.3 | 3.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −37.95% | −17.70% | −35.83% | +88.48% | −15.40% | +47.96% |
| Today | +0.11% | −1.61% | −2.03% | −6.01% | −6.38% | −4.47% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All AGMB news ›AgomAb Therapeutics director buys 5,000 shares
Direct holdings reached 15,000 common shares after David R. Epstein's October 8, 2026 purchase. No Rule 10b5-1 plan is reported in the Form 4. - [Form 4] AgomAb Therapeutics NV Insider Trading Activity AgomAb Therapeutics director buys…
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease October 1, 2026 8:30 AM...
AgomAb Therapeutics (NASDAQ:AGMB) Cut to “Sell” at Wall Street Zen
Posted by Kim Johansen on Sep 30th, 2026 Wall Street Zen lowered shares of AgomAb Therapeutics (NASDAQ:AGMB – Free Report) from a hold rating to a sell rating in a research note published on Sunday,Wall Street Zen reports. View Our Latest…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
kalkinemedia.com1
-
stocktitan.net1
-
themarketsdaily.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.